UDX

Sevilla, Spain Founded: 2012 • Age: 14 yrs
Non-invasive blood-based diagnostics for early cancer detection are developed.
Request Access

About UDX

UDX is a company based in Sevilla (Spain) founded in 2012.. UDX has raised $105.01 million across 7 funding rounds from investors including Olympus, Quest Diagnostics and European Investment Bank. UDX offers products and services including Signal C® and Cancer Platform. UDX operates in a competitive market with competitors including Delfi Diagnostics, Earli, Mirxes, Foresight Diagnostics and Haystack Oncology, among others.

  • Headquarter Sevilla, Spain
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $105.01 M (USD)

    in 7 rounds

  • Latest Funding Round
    $35.01 M (USD), Series C

    Jan 22, 2026

  • Investors
    Olympus

    & 5 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of UDX

UDX offers a comprehensive portfolio of products and services, including Signal C® and Cancer Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Blood test for early detection of colorectal cancer.

Minimally-invasive blood-based solutions for early cancer identification.

People of UDX
Headcount 10-50
Employee Profiles 36
Board Members and Advisors 12
Employee Profiles
People
Francesco Mattia Mancuso
Scientific Integration & Innovation Lead
People
Antonio Carro
Chief Executive Officer
People
Suraj Saksena
Vp, Product Development
People
Iyanu Farukanmi
Quality Specialist

Unlock access to complete

Board Members and Advisors
people
Uri Ladabaum
Advisor
people
Alex Parker
Alex
people
Toni Castells
Advisor
people
Michael Roehrl
Advisor

Unlock access to complete

Funding Insights of UDX

UDX has successfully raised a total of $105.01M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $35.01 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series C — $35.0M
  • First Round
  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2026 Amount Series C - UDX Valuation

investors

Feb, 2025 Amount Debt – Conventional - UDX Valuation

investors

Aug, 2024 Amount Series B - UDX Valuation Quest Diagnostics , Olympus
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in UDX

UDX has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Olympus, Quest Diagnostics and European Investment Bank. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Finance and advisory services for infrastructure projects are provided.
Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by UDX

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - UDX

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Udx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of UDX

UDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Delfi Diagnostics, Earli, Mirxes, Foresight Diagnostics and Haystack Oncology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of DNA sequencing for cancer detection
domain founded_year HQ Location
Early cancer detection tests are developed using synthetic biomarkers.
domain founded_year HQ Location
miRNA-based tests for cancer detection are developed.
domain founded_year HQ Location
Minimally invasive liquid biopsy tests for cancer detection are developed.
domain founded_year HQ Location
Personalized cancer diagnostic tests are provided for minimal residual disease.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Udx

Frequently Asked Questions about UDX

When was UDX founded?

UDX was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is UDX located?

UDX is headquartered in Sevilla, Spain. It is registered at Sevilla, Andalucia, Spain.

Is UDX a funded company?

UDX is a funded company, having raised a total of $105.01M across 7 funding rounds to date.

What does UDX do?

Founded in 2012 in Seville, Spain, the company operates in the biotechnology sector, focusing on non-invasive diagnostics. Blood samples from patients are analyzed using metabolomics to identify early indicators of cancer. Screening tests have been developed for colorectal, lung, and breast cancers, enabling detection through routine blood draws without invasive procedures. Operations center on advancing these diagnostic tools for clinical use.

Who are the top competitors of UDX?

UDX's top competitors include Delfi Diagnostics, Earli and Mirxes.

What products or services does UDX offer?

UDX offers Signal C® and Cancer Platform.

Who are UDX's investors?

UDX has 6 investors. Key investors include Olympus, Quest Diagnostics, European Investment Bank, European Union, and EIC Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available